Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
Paper IDs and full lists are private. Only study types and summaries are shown.
It remains to be determined whether niacin may have clinical utility in particular subgroups, such as statin intolerant patients with hypercholesterolemia or those who cannot achieve a sufficient reduction in LDLc, and whether a potentially beneficial effect o
The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastsatin were higher.
In randomized controlled trials, triglyceride lowering is associated with lower risk of major vascular events, even after adjusting for LDL-C lowering, although the effect is attenuated when REDUCE-IT is excluded.
It is demonstrated that full-dose niacin/moderate-dose simvastatin combination has sustained benefits on atherogenic apoB lipoproteins, at least comparable to high-dose simvastatin, while also raising HDL-cholesterol.
This review summarises the research findings for each source of cognitive impairment for which NAD+ precursor supplementation has been investigated as a therapy and concludes that further properly controlled clinical research is needed to provide definitive an
It is indicated that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL-C.